The balance between IL-1 and IL-1Ra in disease

Cytokine and Growth Factor Reviews

Volumn 13, Issue 4-5, 2002, Pages 323-340

  Arend, William P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ARTERY DISEASE; ARTHRITIS; CANCER; CENTRAL NERVOUS SYSTEM DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOTHELIUM CELL; ENTERITIS; GENE THERAPY; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; INFECTION; KIDNEY DISEASE; LEUKEMIA; LIVER DISEASE; LUNG DISEASE; OSTEOPOROSIS; PANCREAS DISEASE; REVIEW;

ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; GENE THERAPY; HOMEOSTASIS; HUMANS; INFECTION; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; RABBITS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; REPRODUCTION; SIALOGLYCOPROTEINS;

ANIMALIA;

EID: 0036694645     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(02)00020-5     Document Type: Review

References (269)

1. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
2. Arend WP. Interluekin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
3. Sims JE, Giri JG, Dower SK. Short analytical review. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994;72:9-14.
4. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994;12:562-6.
5. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-65.
6. Li X, Commane M, Jiang Z, Stark GR. IL-1-induced NFκB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 recepto-associated kinase (IRAK). Proc Natl Acad Sci USA 2001;98:4461-5.
7. Huang J, Gao X, Ki S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci USA 1997;94:12829-32.
8. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999;398:252-6.
9. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
10. 2-stimulating activity (interleukin-1-like) and inhibitor in urine from a patient with monocytic leukemia. In: Kluger MJ, Oppenheim JJ, Powanda MC, editors. The physiologic, metabolic, and immunologic actions of interleukin 1. New York: Alan R. Liss Inc.; 1985. p. 429-36.
11. Arend WP, D'Angelo S, Massoni RJ, Joslin FG. Interleukin 1 production by human monocytes: effects of different stimuli. In: Kluger MJ, Oppenheim JJ, Powanda MC, editors. The physiologic, metabolic, and immunologic actions of interleukin 1. New York: Alan R. Liss Inc.; 1985. p. 399-407.
12. Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985;134:3868-75.
13. Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, MacDonald HR. A urine inhibitor of interleukin I activity that blocks ligand binding. J Immunol 1987;139:1546-9.
14. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 1989;143:1851-8.
15. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40.
16. Carter DB, Deibel Jr MR, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
17. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6.
18. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1α and IL-1β loci. Genomics 1992;13:654-7.
19. Patterson D, Jones C, Iris H, et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 1993;15:173-6.
20. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1991;88:5232-6.
21. Haskill S, Martin G, Van Le L, et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991;88:3681-5.
22. Muzio M, Polentarutti N, Sironi M, et al. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med 1995;182:623-8.
23. Malyak M, Guthridge JM, Hance KR, Dower SK, Freed JH, Arend WP. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J Immunol 1998;161:1997-2003.
24. Malyak M, Smith Jr MF, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol 1998;161:2004-10.
25. Lawrence W, Tran K, Colquhoun SA, Champliaud MF, Towle CA. Detection of an interleukin-I intracelllar receptor antagonist mRNA variant. Biochem Biophys Res Commun 1998;244:91-5.
26. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991;338:1423-4.
27. Gabay C Jr MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
28. Gabay C, Porter B, Guenette D, Billir B, Arend WP. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1β on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood 1999;93:1299-307.
29. Gabay C, Gigley J, Sipe J, Arend WP, Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol 2001;31:490-9.
30. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7.
31. Hurwitz A, Loukides J, Ricciarelli E, et al. Human intraovarian interleukin-1 (IL-1) system: highly compartmentalized and hormonally dependent regulation of the genes encoding IL-1, its receptor, and its receptor antagonist. J Clin Invest 1992;89:1746-54.
32. Kol S, Donsesky B, Ruutianinen-Altman K, et al. Ovarian interleukin-1 receptor antagonist in rats: gene expression, cellular localization, cyclic variation, and hormonal regulation of a potential determinant of interleukin-1 action. Biol Reprod 1999;61:274-82.
33. Huang HY, Wen Y, Kruessel JS, Raga F, Soong Y-K, Polan ML. Interleukin (IL)-1β regulation of IL-1β and IL-1 receptor antagonist expression in cultured human endometrial stromal cells. J Clin Endocrinol Metab 2001;86:1387-93.
34. Romero R, Sepulveda W, Mazor M, et al. The natural interleukin-1 receptor antagonist in term and preterm parturition. Am J Obstet Gyn 1992;167:863-72.
35. Opp MR, Krueger JM. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol 1991;260:R453-7 (Regulat. Integrative Comp. Physiol. 29).
36. Opp MR, Postlethwaite AE, Seyer JM, et al. Interleukin 1 receptor antagonist blocks somnogenic and pyrogenic responses to an interleukin 1 fragment. Proc Natl Acad Sci USA 1992;89:3726-30.
37. Imeri L, Opp MR, Krueger JM. An IL-1 receptor and an IL-1 receptor antagonist attenuate muramyl dipeptide- and IL-1-induced sleep and fever. Am J Physiol 1993;265:R907-13 (Regulat. Integrative Comp. Physiol. 34).
38. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996;93:11008-13.
39. Rogers HW, Tripp CS, Schreiber RD, Unanue ER. Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994;153:2093-101.
40. Fell HB, Jubb RW. The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum 1977;20:1359-71.
41. Fontana A, Hengartner H, Weber E, Fehr K, Grob PJ, Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982;2:49-53.
42. Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum 1983;26:975-83.
43. Poubelle P, Damon M, Blotman F, Dayer J-M. Production of mononuclear cell factor by mononuclear phagocytes from rheumatoid synovial fluid. J Rheumatol 1985;12:412-7.
44. Wood DD, Ihrie EJ, Hamerman D. Release of interleukin-1 from human synovial tissue in vitro. Arthritis Rheum 1985;28:853-62.
45. Miyasaka N, Sato K, Goto M, et al. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Arthritis Rheum 1988;31:480-6.
46. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749-53.
47. van de Loo AA, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
48. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989;83:647-61.
49. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
50. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
51. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
52. Ulfgren AK, Gröndal L, Lindblad S, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis 2000;59:439-47.
53. van de Loo FAJ, Arntz OJ, Otterness IG, van den Berg WB. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol 1992;19:348-56.
54. van de Loo AAJ, Arntz OJ, Bakker AC, van Lent PLEM, Jacobs MJM, van den Berg WB. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995;146:239-49.
55. van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 1995;38:164-72.
56. Ghivizzani SC, Kang R, Georgescu HI, et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997;159:3604-12.
57. Niki Y, Yamada Y, Seki S, et al. Macrophage- and neutrophil-dominant arthritis in human IL-1 α transgenic mice. J Clin Invest 2001;107:1127-35.
58. Deleuran BW, Chu CQ, Field M, et al. Localization of interleukin-1α type 1, interleukin-1 receptor, and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992;31:801-9.
59. Firestein GS, Berger AE, Tracey DE, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992;149:1054-62.
60. Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992;65:23-9.
61. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993;36:781-9.
62. Beaulieu AD, McColl SR. Differential expression of two major cytokines produced by neutrophils, interleukin-8 and the interleukin-1 receptor antagonist, in neutrophils isolated from the synovial fluid and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1994;37:855-9.
63. Roux-Lombard P, Modoux C, Vischer T, Grassi J, Dayer J-M. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. J Rheumatol 1992;19:517-23.
64. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC. Balance of synovial fluid IL-1β and IL-1 receptor antagonist mid recovery from Lyme arthritis. Lancet 1993;341:146-8.
65. 2/collagenase production by human dermal fibroblasts and synovial cells. Immunobiology 1990;180:316-27.
66. Seckinger P, Yaron I, Meyer FA, Yaron M, Dayer J-M. Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. Arthritis Rheum 1990;33:1807-14.
67. Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
68. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
69. Fukomoto T, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga M. Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits. Inflamm Res 1996;45:479-85.
70. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993;151:4344-51.
71. Lubberts E, Joosten LAB, Helsen MMA, van den Berg WB. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998;10:361-9.
72. Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC. Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991;59:4436-42.
73. Kuiper S, Joosten LAB, Bendele AM, et al. Different roles of tumor necrosis factor a and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
74. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
75. van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Berssellar LAM, Vermeer H, van den Berg WB. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995;22:2250-8.
76. Arner EC, Harris RR, DiMeo TM, Collins RC, Galbraith W. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J Rheumatol 1995;22:1338-46.
77. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Arthritis Rheum 1999;42:498-506.
78. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:1798-805.
79. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
80. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
81. Joosten LAB, Helsen MMA, Saxne T, van de Loo FAJ, Heinegård D, van den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
82. Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
83. Feretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994;94:449-53.
84. Thomas TK, Will PC, Srivastava A, et al. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions 1991;34:187-90.
85. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65-71.
86. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, Sartor RB. Tissue interleukin-1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994;106:960-72.
87. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
88. Casini-Raggi V, Kam L, Chong YJT, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-40.
89. Daig R, Rogler G, Aschenbrenner E, et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 2000;46:350-8.
90. Böeker U, Damião A, Holt L, et al. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology 1998;115:1426-38.
91. Mulligan MS, Ward PA. Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-α and IL-1. J Immunol 1992;149:331-9.
92. Shanley TP, Peters JL, Jones ML, Chensue SW, Kunkel SL, Ward PA. Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury. J Clin Invest 1996;97:963-70.
93. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993;5:57-61.
94. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirement for tumor necrosis factor-α and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993;143:453-63.
95. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Resp Cell Mol Biol 1994;11:664-75.
96. Leff JA, Bodman ME, Cho OJ, et al. Post-insult treatment with interleukin-1 receptor antagonist decreases oxidative lung injury in rats given intratracheal interleukin-1. Am J Resp Crit Care Med 1994;150:109-12.
97. Selig W, Tocker J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea pigs. Eur J Pharmacol 1992;213:331-6.
98. Okada S, Inoue H, Yamauchi K, et al. Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 1995;95:1236-45.
99. Janson RW, King Jr TE, Hance KR, Arend WP. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Resp Dis 1993;148:495-503.
100. Smith DR, Kunkel SL, Standiford TJ, et al. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. J Resp Crit Care Med 1995;151:1965-73.
101. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6.
102. Mikuniya T, Nagai S, Takeuchi M, et al. Significance of the interleukin-1 receptor antagonist/interleukin-1β ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration 2000;67:389-96.
103. Tsao TCY, Hong JH, Li LF, Hsieh MJ, Liao SK, Chang KSS. Imbalances between tumor necrosis factor-α and its soluble receptor forms, and interleukin-1β and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000;117:103-9.
104. Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Resp Crit Care Med 1999;159:487-94.
105. Tam FWK, Smith J, Cashman SJ, Wang Y, Thompson EM, Rees AJ. Glomerular expression of interleukin-1 receptor antagonist and intelieukin-1β genes in antibody-mediated glomerulonephritis. Am J Pathol 1994;145:126-36.
106. Tang WW, Feng L, Vannice JL, Wilson CB. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 1994;93:273-9.
107. Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995;47:1303-9.
108. Karkar AM, Tam FWK, Steinkasserer A, et al. Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble TNF receptor. Kidney Int 1995;48:1738-46.
109. Tesch GH, Lan HY, Atkins RC, Nikolic-Paterson DJ. Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis. Am J Pathol 1997;151:141-50.
110. Yamagishi H, Yokoo T, Imasawa T, Mitarai T, Kawamura T, Utsunomiya Y. Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. J Immunol 2001;166:609-16.
111. Kim DC, Reitz B, Carmichael DF, Bloedow DC. Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci 1995;84:575-80.
112. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-6.
113. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1β, TNFα and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 1995;154:882-92.
114. Rostoker G, Rymer J-C, Gagnard G, Petit-Phar M, Griuncelli M, Pilatte Y. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy. Clin Exp Immunol 1998;114:468-76.
115. Teppo AM, Honkanen E, Ahonen J, Gronhagen-Riska C. Does increased urinary interleukin-1 receptor antagonist/interleukin-1β ratio indicate good prognosis in renal transplant recipients? Transplantation 1998;66:1009-14.
116. Fujioka N, Mukaida N, Harada A, et al. Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice. J Leukoc Biol 1995;58:90-8.
117. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994;98:71-7.
118. Gramantieri L, Casali A, Trerè D, et al. Imbalance of IL-1β and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Clin Exp Immunol 1999;115:515-20.
119. Conti F, Breton S, Batteux F, et al. Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy. Am J Pathol 2000;157:1685-92.
120. Norman J, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995;117:648-55.
121. Fink G, Yang J, Carter G, Norman J. Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res 1997;67:94-7.
122. Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Crit Care Med 1999;27:749-55.
123. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000;47:546-52.
124. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
125. McCarthy Jr PL, Abhyankar S, Neben S. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915-8.
126. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR. Interluekin-1 or tumor necrosis factor-α antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 1995;60:1371-4.
127. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
128. Antin JH, Weisdorf D, Nueberg D, et al. Interleukin-1 blockade does not prevent acute graft versus host disease (GVHD). Results of a randomized, double blind, placebo-controlled trial of interleukin 1 receptor antagonist (IL-1RA). Blood 1999;94:152a (Abstract).
129. Tao M, Li B, Nayini J, et al. SCR, IL-1β, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 2000;12:699-707.
130. Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991;78:1476-84.
131. Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 1994;84:3142-7.
132. Vidal-Vanaclocha F, Amézaga C, Asumendi A, et al. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994;54:2667-72.
133. Hsieh TC, Chiao JW. Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 1995;95:119-23.
134. Yamada Y, Karasaki H, Matsushima K, et al. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 1999;79:1059-67.
135. Oelmann E, Kraemer A, Serve H, et al. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 1997;71:1066-76.
136. Iizuka N, Hazama S, Hirose K, et al. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 1999;142:179-84.
137. Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer J-M, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990;145:4181-4.
138. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
139. Kimble RB, Kitazawa R, Vannice JL, Pacifici R. Persistent bone-sparing effect of interleukin-1 receptor antagonist: a hypothesis of the role of IL-1 in ovariectomy-induced bone loss. Calcif Tissue Int 1994;55:260-5.
140. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 1994;94:2397-406.
141. Abrahamsen B, Shalhoub V, Larson EK, Eriksen EF, Beck-Nielsen H, Marks Jr SC. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. Bone 2000;26:137-45.
142. Sandler S, Eizirik DL, Svensson C, Strandell E, Welsh M, Welsh N. Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 1991;10:241-53.
143. Eizirik DL, Tracey DE, Bendtzen K, Sandler S. An interleukin-1 receptor antagonist protein protects insulin-producing β cells against suppressive effects of interleukin-1β. Diabetologia 1991;34:445-8.
144. Mandrup-Poulsen T, Zumsteg U, Reimers J, et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993;5:185-91.
145. Sandberg JO, Andersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994;202:543-8.
146. Sandberg JO, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 1997;108:314-7.
147. Netea MG, Hancu N, Blok WL, et al. Interleukin 1β, tumour necrosis factor-α and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine 1997;9:284-7.
148. Allan SM. The role of pro- and antiinflammatory cytokines in neurodegeneration. Ann N Y Acad Sci 1998;866:84-93.
149. Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 1994;55:153-60.
150. Licino J, Wong ML, Gold PW. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991;129:562-4.
151. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994;130:362-7.
152. Garcia JH, Liu KF, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol 1995;147:1477-86.
153. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996;16:932-40.
154. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996;138:206-13.
155. Stroemeer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997;17:597-604.
156. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role of IL-1α and IL-1β in ischemic brain damage. J Neurosci 2001;15:5528-34.
157. Loddick SA, Wong ML, Bongiorno PB, Gold PW, Licinio J, Rothwell NJ, Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 1997;234:211-5.
158. Vezzani A, Moneta D, Conti M, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 2000;97:11534-9.
159. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licino J, Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic
160. Miller LC, Isa S, Vannier E, Georgilis K, Cteere AC, Dinarello CA. Live Borrelia burgdoferi preferentially activate interleukin-1β gene expression and protein synthesis over the interleukin-1 receptor antagonist. J Clin Invest 1992;90:906-12.
161. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
162. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents E. coli-induced shock in rabbits. FASEB J 1991;5:338-43.
163. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991;173:1029-32.
164. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
165. Poli G, Kinter AL, Fauci AS. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1994;91:108-12.
166. Goletti D, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1β and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. J Immunol 1996;156:3501-8.
167. Loré K, Sönnerborg A, Olsson J, et al. HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation. AIDS 1999;13:2013-21.
168. Zavala F, Rimaniol AC, Boussin F, Dormont D, Bach JF, Descamps-Latscha B. HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. J Immunol 1995;155:2784-93.
169. Thea DM, Porat R, Nagimbi K, et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med 1996;124:757-62.
170. Kreuzer KA, Dayer J-M, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1β, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 1997;109:54-8.
171. Clausell N, Rabinovitch M. Upregulation of fibronectin synthesis by interleukin-1β in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets. J Clin Invest 1993;92:1850-8.
172. Elhage R, Maret A, Pieraggi M-T, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998;97:242-4.
173. Chamberlain J, Gunn J, Francis S, Holt C, Crossman D. Temporal and spatial distribution of interleukin-1β in balloon injured porcine coronary arteries. Cardiovasc Res 1999;44:156-65.
174. Wang X, Romanic AM, Yue T-L, Feuerstein GZ, Ohlstein EH. Expression of interleukin-1β, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Commun 2000;271:138-43.
175. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2394-400.
176. Neumann DA, Lane JR, Allen GS, Herskowitz A, Rose NR. Viral myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis? Clin Immunol Immunopathol 1993;68:181-90.
177. Shiraishi M, Csete M, Yasunaga C, et al. The inhibitor cytokine interleukin-1 receptor antagonist synergistically augments cyclosporine immunosuppression in a rat cardiac allograft model. J Surg Res 1995;58:465-70.
178. Wang CY, Naka Y, Liao H, et al. Cardiac graft intercellular adhesion molecule-1 (ICAM-1) and interleukin-1 expression mediate primary isograft failure and induction of ICAM-1 in organs remote from the site of transplantation. Circ Res 1998;82:762-72.
179. Nicklin MJH, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-11.
180. Watson JM, Lofquist AK, Rinehart CA, et al. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1β. J Immunol 1995;155:4467-75.
181. Higgins GC, Wu Y, Postlethwaite AE. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1α. J Immunol 1999;163:3969-75.
182. Wessendorf JHM, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1α precursor. J Biol Chem 1993;268:22100-4.
183. McMahon GA, Garfinkel S, Prudovsky I, Hu X, Maciag T. Intracellular precursor interleukin (IL)-1α, but not mature IL-1α is able to regulate human endothelial cell migration in vitro. J Biol Chem 1997;272:28202-5.
184. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997;94:508-13.
185. Corradi A, Franzi AT, Rubartelli A. Synthesis and secretion of interleukin-1α and interleukin-1 receptor antagonist during differentiation of cultured keratinocytes. Exp Cell Res 1995;217:355-62.
186. Levine SJ, Wu T, Shelhamer JH. Extracellular release of the type I intracellular IL-1 receptor antagonist from human airway epithelial cells. J Immunol 1997;158:5949-57.
187. Yoon HJ, Zhu A, Gwaltney Jr JM, Elias JA. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: a potential mechanism of symptom resolution. J Immunol 1999;162:7461-9.
188. Steinkasserer A, Koelble K, Sim RB. Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL1RN). Nucl Acids Res 1991;19:5095.
189. Tarlow JK, Blakemore AIF, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4.
190. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000;59:160-4.
191. Clay FE, Cork MJ, Tarlow JK, et al. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet 1994;94:407-10.
192. Tarlow JK, Clay FE, Cork MJ, et al. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994;103:387-90.
193. Tarlow JK, Cork MJ, Clay FE, et al. Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol 1997;136:132-48.
194. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
195. Tountas NA, Casini-Raggi V, Yang H. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999;117:806-13.
196. Bouma G, Crusisu JBA, García-González MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294-300.
197. Craggs A, West S, Curtis A, et al. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand J Gastroenterol 2001;11:1173-8.
198. Ishizuka K, Sugimura K, Homma T, et al. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1β ratio in the colonic mucosa of ulcerative colitis. Digestion 2001;63(Suppl 1):22-7.
199. Crusius JBA, Peña AS, van Oosten BW, et al. Interleukin-1 receptor antagonist gene polymorphism an multiple sclerosis. Lancet 1995;346:979-80.
200. Schrijver HM, Crusius JBA, Uitdehagg BMJ, et al. Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999;52:595-9.
201. Sciacca FL, Ferri C, Vandenbroeck K, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999;52:1896-8.
202. de al Concha EG, Arroyo R, Crusisu JBA, et al. Combined effect of HLA-DRBI*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 1997;80:172-8.
203. Semana G, Yaouang J, Alizadeh M, Clanet M, Edan G. Interleukin-1 receptor antagonist gene in multiple sclerosis. Lancet 1997;349:476.
204. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1β and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000;106:220-7.
205. Luomala M, Lehtimäki T, Elovaara I, et al. A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J Neurol Sci 2001;185:123-7.
206. Niino M, Kikuchi S, Fukazawa T, Yabe I, Sasaki H, Tashiro K. Genetic polymorphisms of IL-1β and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J Neuroimmunol 2001;118:295-9.
207. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome. Clin Immuol Immunopathol 1998;87:309-13.
208. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380-5.
209. Suzuki H, Matsui Y, Kashiwagi H. Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:389-90.
210. Tjernström F, Hellmer G, Nived O, Truedsson L, Sturfelt G. Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17, DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999;8:103-8.
211. Rider LG, Artlett CM, Foster CB, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000;121:47-52.
212. Vencovsky J, Jarosova K, Ruzickova S, et al. Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. Arthritis Rheum 2001;44:2387-91.
213. Cantagrel A, Navaus F, Loubet-Lescoulie L, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms. Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
214. Buchs N, di Giovine F, Vannier E, Duff G, Lyon PM. IL-1β, and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Arthritis Rheum 2000;43:S324 (Abstract).
215. Liu Z-H, Cheng Z-H, Yu Y-S, Tang A, Li L-S. Interleukin-1 receptor antagonist allele: is it a genetic link between Henoch-Schönlein nephritis and IgA nephropathy? Kidney Int 1997;51:1938-42.
216. Shu K-H, Lee S-H, Cheng C-H, Wu M-J, Lian J-D. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathy. Kidney Int 2000;58:783-9.
217. El-Omar EM, Carrington M, Chow W-H, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
218. Blakemore AIF, Cox A, Gonzalez AM, et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996;97:369-74.
219. Fang XM, Schröder S, Hoeft A, Süber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-4.
220. Parkhill JM, Henning BJW, Chapple ILC, Heasman PA, Taylor JJ. Association of interleukin-1 gene polymorphisms with early-onset periodontitis. J Clin Periodontol 2000;27:682-9.
221. Mao X-Q, Kawai M, Yamashita T, et al. Imbalance production between interleukin-1β (IL-1β) and IL-1 receptor antagonist (IL-1Ra) in bronchial asthma. Biochem Biophys Res Commun 2000;276:607-12.
222. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Resp Crit Care Med 2000;162:755-8.
223. Yucesoy B, Vallyathan V, Landsittel DP, et al. Polymorphisms of the IL-1 gene complex in coal miners with silicosis. Am J Ind Med 2001;39:286-91.
224. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001;113:807-13.
225. Unfried G, Tempfer C, Schneeberger C, Widmar B, Nagele F, Huber JC. Interleukin 1 receptor antagonist polymorphism in women with idiopathic recurrent miscarriage. Fertil Steril 2001;75:683-7.
226. Garcia-Gonzalez MA, Lanas A, Santolaria S, Crusisu JBA, Serrano MT. The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. Clin Exp Immunol 2001;125:368-75.
227. Hacker UT, Erhardt S, Tschöp K, Jelinek T, Endres S. Influence of IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1β after live yellow fever vaccination. Clin Exp Immunol 2001;125:465-9.
228. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
229. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998;47:195-8.
230. Carter MJ, Jones S, diGiovine FS, et al. Allele 2 of IL-1RN gene polymorphism is associated with reduced expression of IL-1ra in ulcerative colitis. Gastoenterology 1998;114:3882 (Abstract).
231. Francis SE, Camp NJ, Dewberry RM, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;99:861-6.
232. Kastrati A, Koch W, Berger P, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000;36:2168-73.
233. Francis SE, Camp NJ, Burton AJ, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart 2001;86:336-40.
234. Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J Am Coll Cardiol 2001;38:712-7.
235. Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of IL-1 receptor blockade on human response to endotoxemia. J Immunol 1995;154:1499-507.
236. Fisher Jr CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
237. Fisher Jr CJ, Dhainault J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. J Am Med Assoc 1994;271:1836-43.
238. Bendele A, Sennello G, McAbee T, Frazier J, Chlipala E, Rich B. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats. J Rheumatol 1999;26:1225-9.
239. Feige U, Hu Y-L, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57:1457-70.
240. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43:2648-59.
241. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
242. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;31:2196-204.
243. Cunnane G, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001;20:62-9.
244. Jiang Y, Genant HK, Watt I, et al. A multicenter double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1001-9.
245. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human interleukin-1 receptor antagonist (IL-1ra) in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
246. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993;90:10764-8.
247. Hung GL, Galea-Lauri J, Mueller GM, et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1994;1:64-9.
248. Roessler BJ, Hartman JW, Vallance DK, Latta JM, Janich SL, Davidson BL. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 1995;6:307-16.
249. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156:3558-62.
250. Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996;93:402-6.
251. Bakker AC, Joosten LAB, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900.
252. Nguyen KHY, Boyle DL, McCormack JE, Chada S, Jolly DJ, Firestein GS. Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis. J Rheumatol 1998;25:1118-25.
253. Oligino T, Ghivizzani SC, Wolfe D, et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999;6:1713-20.
254. Pan R-Y, Chen S-L, Xiao X, Liu D-W, Peng H-J, Tsao Y-P. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000;43:289-97.
255. Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998;95:4613-8.
256. Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler BJ. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J Clin Invest 1995;96:2454-60.
257. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Arthritis Rheum 1996;39:1535-44.
258. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by IL-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-9.
259. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints. Am J Pathol 1999;154:1159-69.
260. Betz AL, Yang G-Y, Davidson BL. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995;15:547-51.
261. Hagan P, Barks JDE, Yabut M, Davidson BL, Roessler B, Silverstein FS. Adenovirus-mediated over-expression of interleukin-1 receptor antagonist reduces susceptibility to excitotoxic brain injury in perinatal rats. Neuroscience 1996;75:1033-45.
262. Yang G-Y, Zhao Y-J, Davidson BL, Betz AL. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997;751:181-8.
263. Yang G-Y, Liu XH, Kadoya C, et al. Attenuation of ischemic inflammatory response in mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. J Cereb Blood Flow Metab 1998;18:840-7.
264. Yang G-Y, Mao Y, Zhu L-F, et al. Attenuation of temporary focal cerebral ischemic injury in the mouse following transfection with interleukin-1 receptor antagonist. Mol Brain Res 1999;72:129-37.
265. Yang G-Y, Mao Y, Zhou L-F, Gong C, Ge H-L, Betz AL. Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. Mol Brain Res 1999;65:143-50.
266. Giannoukakis N, Rudert WA, Givizzani SC, et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β-induced β-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999;48:1730-6.
267. Nakano A, Matsumori A, Kawamoto S, et al. Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 2001;12:1289-97.
268. Suzuki K, Murtuza B, Smolenski R, et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 2001;104(Suppl I):1308-13.
269. Robbins E, Ghivizzani SC, Herndon JH, et al. Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum 1999;42:S17 (Abstract).